 417 million people worldwide are infected with HSV2, which causes genital ulcer disease and can be transmitted to intimate partners. A trivalent subunit antigen vaccine containing GC2, GD2, and GE2 subunit antigens has been developed and evaluated in guinea pigs previously infected with HSV2. The vaccine significantly boosts ELISA titers and neutralizing antibody titers, reduces the frequency of recurrent genital lesions and vaginal shedding of HSV2 DNA by approximately 50%, and almost totally eliminates vaginal shedding of replication-competent virus, making it a worthy candidate for immunotherapy of genital herpes. This article was authored by Sita Awasthi, Lauren M. Hook, Caroline Eshaw, and others.